On the fourth and final day of the American Society of Hematology (ASH) 2011 annual meeting, there was one session in the morning with a number of important myeloma-related presentations.

The key findings of those presentations are summarized in this article.

Treatment Of High-Risk Smoldering Myeloma

Dr. María-Victoria Mateos from the University Hospital in Salamanca, Spain, kicked off the session.

She gave a presentation reviewing a Phase 3 trial she and her colleagues are conducting on the treatment of high-risk smoldering myeloma patients with Revlimid (lenalidomide) and dexamethasone (Decadron) (

As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma ther­a­pies.

The afternoon myeloma sessions were focused, in fact, on potential new ther­a­pies.

The Beacon's pre­vi­ous ASH 2011 update covered the afternoon presentations about carfilzomib and pomalidomide, two potential myeloma ther­a­pies that are in the late stages of devel­op­ment.

This update covers the afternoon's presentations about four other potential new myeloma ther­a­pies -- MLN9708, panobinostat, …

The afternoon sessions of the third day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego were just as awash with myeloma-related presentations as were the morning sessions.

Many of the afternoon sessions were devoted to two particular potential new myeloma treat­ments: car­filz­o­mib and pomalidome.

Those presentations will be covered in this article, while presentation from the afternoon sessions that were about other new ther­a­pies will be summarized in the final daily update for the meeting's third day.

Carfilzomib

Carfilzomib (Kyprolis) is an investigational drug that belongs to the …

Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma.  Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.

The morning presentations about therapies combining current myeloma drugs will be covered in this update.  Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be covered in …

Yesterday was the third day of the American Society of He­ma­tol­ogy (ASH) 2011 Annual Meeting in San Diego, and it was packed full with mul­ti­ple myeloma-related pre­sen­ta­tions. Presentations started early in the morn­ing and con­tinued through the afternoon.

The morn­ing pre­sen­ta­tions about po­ten­tial new myeloma ther­a­pies will be covered in this up­date, and pre­sen­ta­tions from the rest of the day will be covered in addi­tional up­dates.

MLN9708

During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer In­sti­tute in Boston pre­sented re­­sults from a Phase 1 study of …

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.

Predicting Response To Immunomodulatory Drugs

During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma.  Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide.  Another study (abstract) …

Yesterday was the first day of the American Society of He­ma­tol­ogy (ASH) 2011 annual meeting, which is being held in San Diego.

Although the day featured no oral pre­sen­ta­tions of new myeloma-related re­search, it started with an in­ter­est­ing educational session focused on mul­ti­ple myeloma.

There also were a num­ber of poster pre­sen­ta­tions during the day summarizing im­por­tant new re­search findings.

The educational session in the morn­ing featured three pre­sen­ta­tions by lead­ing myeloma spe­cialists.

Induction Therapy And Maintenance Treatment

The first pre­sen­ta­tion was by Dr. Donna Reece of the Princess Margaret Hospital in …